cagrilintide clinical trials results New in the August 14, 2025, issue of NEJM: ⁣ ⁣ Cagrilintide–Semaglutide for Overweight or Obesity (REDEFINE 1 phase 3a trial)⁣ ⁣ Cagrilintide–Semaglutide for Overweight and Diabetes (REDEFINE 2 phase 3a trial)⁣ ⁣ Subcutaneous Cagrilintide, Semaglutide Shows Significant

Solomon, E

Mean weight loss -20.4% vs -3.0% placebo

Potential benefits and considerations of DSIP therapy Potential benefits (based on available research) May support natural sleep architecture without pharmacological sedation Non-habit forming does not appear to carry dependency or tolerance risks comparable to benzodiazepines or opiates No reported morning grogginess in available studies Possible complementary effects on stress, pain, and immune regulation May support wellness goals related to longevity, cellular health, and metabolic support Considerations and limitations DSIP is investigational large-scale human clinical trials are limited Injectable forms require proper handling, reconstitution, and refrigeration Effects vary between individuals not all users report the same outcomes Cost may be higher than over-the-counter sleep aids Access requires a consultation with a qualified provider Safety profile and side effects The available research on DSIP suggests a generally favorable safety profile when used under professional supervision

Most peptides are rapidly degraded by digestive enzymes if taken orally